

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): November 12, 2020

Atreca, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-38935
(Commission File Number)

27-3723255
(I.R.S. Employer Identification Number)

450 East Jamie Court, South San Francisco, California
(Address of Principal Executive Offices)

94080
(Zip Code)

(650) 595-2595
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, \$0.0001 par value per share	BCEL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2020, Atreca, Inc. (the "*Company*") issued a press release reporting its financial results for the quarter ended September 30, 2020 and its recent corporate developments. A copy of such press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

The information in Item 2.02 of this Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, or into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as expressly set forth by reference in such a filing.

Item 9.01. Financial Statements and Exhibits.**(d) Exhibits****Exhibit
Number****Exhibit Description**

<u>99.1</u>	<u>Press Release titled "Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments," dated November 12, 2020, furnished herewith</u>
-----------------------------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Atreca, Inc.

Dated: November 12, 2020

By: /s/ Herbert Cross
Herbert Cross
Chief Financial Officer

Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

“We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021,” said John Orwin, Chief Executive Officer. “We recently presented preclinical data at SITC 2020 further highlighting the potential for ATRC-101 as a combination therapy with checkpoint inhibitors targeting the PD-1/PD-L1 axis. We expect to initiate combination studies with a checkpoint inhibitor as well as with chemotherapy, and to commence monotherapy expansion cohorts, in 2021.”

Recent Developments and Highlights

- Screening in the Phase 1b first-in-human study evaluating ATRC-101 in patients with select solid tumor cancers is ongoing, and patients are currently being enrolled in the third dose cohort. To date, seven clinical trial sites have been activated, including two additional sites in the third quarter of 2020, and Atreca expects to announce initial summary data from the study in the first half of 2021. In addition to monotherapy expansion cohorts, clinical trials of ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic are planned for 2021.
- Atreca presented two posters describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020). The presentations provide insight into the cooperation between checkpoint inhibitors targeting the PD-1/PD-L1 axis and ATRC-101 as well as the potent single-agent activity of ATRC-101 in syngeneic mouse tumor models. Both posters are currently available on Atreca’s website.

Third Quarter 2020 Financial Results

- As of September 30, 2020, cash, cash equivalents and investments totaled \$259.5 million.
- Research and development expenses for the three months ended September 30, 2020 were \$16.8 million, including non-cash share-based compensation expense of \$1.6 million.
- General and administrative expenses for the three months ended September 30, 2020 were \$6.6 million, including non-cash share-based compensation expense of \$1.9 million.
- Atreca reported a net loss of \$22.9 million, or basic and diluted net loss per share attributable to common stockholders of \$0.66, for the three months ended September 30, 2020.

About Atreca, Inc.

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements

This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “continued,” “anticipate,” “potential,” “expect,” “believe,” “planned,” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Atreca, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

	<u>September 30, 2020</u>	<u>December 31, 2019</u>
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 133,072	\$ 157,954
Investments	126,192	14,663
Prepaid expenses and other current assets	4,898	3,502
Total current assets	<u>264,162</u>	<u>176,119</u>
Property and equipment, net	7,783	5,771
Long-term investments	205	10,799
Deposits and other	3,043	3,026
Total assets	<u>\$ 275,193</u>	<u>\$ 195,715</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities		
Accounts payable	\$ 2,524	\$ 2,133
Accrued expenses	5,309	5,395
Other current liabilities	1,442	419
Total current liabilities	<u>9,275</u>	<u>7,947</u>
Capital lease obligations, net of current portion	17	53
Deferred rent	4,621	763
Total liabilities	<u>13,913</u>	<u>8,763</u>
Stockholders' equity		
Common stock	4	3
Additional paid-in capital	488,593	351,039
Accumulated other comprehensive income	117	16
Accumulated deficit	<u>(227,434)</u>	<u>(164,106)</u>
Total stockholders' equity	<u>261,280</u>	<u>186,952</u>
Total liabilities and stockholders' equity	<u>\$ 275,193</u>	<u>\$ 195,715</u>

Atreca, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)

	<u>Three Months Ended September 30,</u>		<u>Nine Months Ended September 30,</u>	
	<u>2020</u>	<u>2019</u>	<u>2020</u>	<u>2019</u>
Expenses				
Research and development	\$ 16,808	\$ 12,812	\$ 45,198	\$ 40,447
General and administrative	6,614	4,864	20,195	10,919
Total expenses	<u>23,422</u>	<u>17,676</u>	<u>65,393</u>	<u>51,366</u>
Interest and other income (expense)				
Other income	353	619	987	1,805
Interest income	142	1,189	1,082	2,328
Interest expense	(1)	(1)	(3)	(5)
Preferred stock warrant liability revaluation	—	—	—	(123)
Foreign exchange loss	—	(1)	—	(1)
Loss on disposal of property and equipment	—	—	—	(7)
Loss before Income tax expense	<u>(22,928)</u>	<u>(15,870)</u>	<u>(63,327)</u>	<u>(47,369)</u>
Income tax expense	<u>(1)</u>	<u>(1)</u>	<u>(1)</u>	<u>(2)</u>

Net loss	\$ (22,929)	\$ (15,871)	\$ (63,328)	\$ (47,371)
Net loss per share, basic and diluted	\$ (0.66)	\$ (0.57)	\$ (2.09)	\$ (4.03)
Weighted-average shares used in computing net loss per share, basic and diluted	34,723,888	27,949,682	30,313,047	11,747,825

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251, ext. 251
agray@atreca.com

Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com
Source: Atreca, Inc.